Galapagos NV (GLPG) Analysts See $-0.70 EPS

February 14, 2018 - By Adrian Erickson

 Galapagos NV (GLPG) Analysts See $ 0.70 EPS

Analysts expect Galapagos NV (NASDAQ:GLPG) to report $-0.70 EPS on February, 23.They anticipate $1.75 EPS change or 166.67 % from last quarter’s $1.05 EPS. After having $-0.85 EPS previously, Galapagos NV’s analysts see -17.65 % EPS growth. The stock decreased 2.05% or $2.36 during the last trading session, reaching $112.83. About 80,233 shares traded. Galapagos NV (NASDAQ:GLPG) has risen 65.27% since February 14, 2017 and is uptrending. It has outperformed by 48.57% the S&P500.

Galapagos NV (NASDAQ:GLPG) Ratings Coverage

Among 9 analysts covering Galapagos NV (NASDAQ:GLPG), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Galapagos NV had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Thursday, August 10 with “Buy”. Stifel Nicolaus maintained Galapagos NV (NASDAQ:GLPG) rating on Friday, July 28. Stifel Nicolaus has “Hold” rating and $8300 target. The firm earned “Buy” rating on Tuesday, August 30 by Janney Capital. As per Friday, August 11, the company rating was upgraded by Stifel Nicolaus. BTIG Research maintained Galapagos NV (NASDAQ:GLPG) on Monday, November 20 with “Buy” rating. The firm has “Neutral” rating given on Friday, July 7 by Janney Capital. The firm has “Neutral” rating given on Monday, January 25 by Goldman Sachs. The stock of Galapagos NV (NASDAQ:GLPG) has “Overweight” rating given on Monday, May 2 by Morgan Stanley. Nomura maintained Galapagos NV (NASDAQ:GLPG) rating on Friday, August 11. Nomura has “Buy” rating and $124 target. The stock of Galapagos NV (NASDAQ:GLPG) earned “Neutral” rating by Credit Suisse on Monday, September 28.

Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The company has market cap of $5.53 billion. The Company’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis patients in Phase Ib trial. It currently has negative earnings. The firm has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106.

More notable recent Galapagos NV (NASDAQ:GLPG) news were published by: Marketwatch.com which released: “Galapagos NV ADR” on September 24, 2016, also Benzinga.com with their article: “33 Biggest Movers From Friday” published on December 18, 2017, Barrons.com published: “Galapagos Is More Attractive–But Don’t Buy It Just Yet” on July 07, 2017. More interesting news about Galapagos NV (NASDAQ:GLPG) were released by: Benzinga.com and their article: “Morgan Stanley Expects Galapagos Shares To Rise 10%” published on August 10, 2017 as well as Quotes.Wsj.com‘s news article titled: “News Galapagos NV ADRGLPG” with publication date: May 09, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: